Skip to content

A randomized double-blind placebo-controlled trial of Yiqi Shengjin Powder for the treatment of patients with type 2 diabetes and coronary heart disease with qi-yin deficiency syndrome.

A randomized double-blind placebo-controlled trial of Yiqi Shengjin Powder for the treatment of patients with type 2 diabetes and coronary heart disease with qi-yin deficiency syndrome.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000742
Enrollment
Unknown
Registered
2024-11-26
Start date
2025-03-01
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes and coronary heart disease with qi-yin deficiency syndrome

Interventions

Yiqi Shengjin San Group:Addition of Yiqi Shengjin San on top of oral western medicine treatment. Yiqi Shengjin San should be taken orally with warm boiled water after an interval of 0.5h with western
placebo group:A placebo was added to the conventional oral western medicine treatment. Placebo is prepared by Beijing Institute of Traditional Chinese Medicine the dosage form is granule preparation s

Sponsors

Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-80 years old (both ends inclusive) ; (2) Meet the diagnostic criteria for type 2 diabetes mellitus and stable coronary heart disease; (3) Meet the diagnostic criteria of TCM Xiaoke Disease and Chest Painbasedon; (5) Meet the diagnostic criteria of TCM syndrome differentiation standards for qi and yin deficiency syndrome; (4) patients with HbA1c in 6.0%-7.5%; (5) Not regularly taking any preparations containing traditional Chinese medicine ingredients in 1 month before enrollment; (6) The subject or his/her legal representative voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with acute myocardial infarction; (2) Non type 2 diabetes patients with elevated blood sugar. (3) Patients with acute complications of diabetes including diabetes ketosis ketoacidosis hyperosmolar coma etc. (4) Patients receiving insulin or GLP-1 receptor agonists. (5) Patients with obvious liver dysfunction (alanine aminotransferase or aspartate aminotransferase exceeding twice the upper limit of normal) or renal dysfunction (serum creatinine>265.2 umol/l); (6) Pregnant or lactating women; (7) Individuals who are allergic to the experimental drug; (8) Not willing to cooperate and mentally ill patients.

Design outcomes

Primary

MeasureTime frame
seattle angina questionnaire;HbA1c;

Secondary

MeasureTime frame
traditional Chinese medicine syndrome scores;glucose variability;Clinical efficacy of traditional Chinese medicine syndromes;Percentage of glucose less than 3.9 mmol/L;Major Adverse Cardiovascular Events;Percentage of glucose greater than or equal to 3.9 mmol/L and less than or equal to 10 mmol/L;glucose standard deviation;Percentage of glucose greater than 10 mmol/L;

Countries

China

Contacts

Public ContactSHANG-JuJu

Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University

shangjuju@bjzhongyi.com13301132680

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026